Circulating microRNA profiles of Ebola virus infection

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Duy, Janice ^a   Koehler, Jeffrey W ^a   Honko, Anna N ^b,d   Schoepp, Randal J ^a   Wauquier, Nadia ^c   Gonzalez, Jean Paul ^c   Pitt, M Louise ^b   Mucker, Eric M ^b   Johnson, Joshua C ^b,d   O'Hearn, Aileen ^a   Bangura, James ^c   Coomber, Moinya ^c   Minogue, Timothy D ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b Virology Division US Army Medical Institute of Infectious Diseases   (United States)

^c METABIOTA INC   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MICRORNA;

ADOLESCENT; ADULT; ANIMAL; BIOLOGY; BLOOD; CLUSTER ANALYSIS; DISEASE MODEL; EBOLAVIRUS; FEMALE; GENE EXPRESSION PROFILING; GENETICS; HEMORRHAGIC FEVER, EBOLA; HOST PATHOGEN INTERACTION; HUMAN; MALE; MIDDLE AGED; PHYSIOLOGY; PROCEDURES; RHESUS MONKEY; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

ADOLESCENT; ADULT; ANIMALS; BIOMARKERS; CLUSTER ANALYSIS; COMPUTATIONAL BIOLOGY; DISEASE MODELS, ANIMAL; EBOLAVIRUS; FEMALE; GENE EXPRESSION PROFILING; HEMORRHAGIC FEVER, EBOLA; HOST-PATHOGEN INTERACTIONS; HUMANS; MACACA MULATTA; MALE; MICRORNAS; MIDDLE AGED; VIRAL LOAD; YOUNG ADULT;

EID: 84964529047     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep24496     Document Type: Article

References (69)

1. Blackley, D. J. et al. Rapid Intervention to Reduce Ebola Transmission in a Remote Village-Gbarpolu County, Liberia, 2014. 175-178 (Centers for Disease Control and Prevention, 2015).
2. Schieffelin, J. S. et al. Clinical Illness and Outcomes in Patients with Ebola in Sierra Leone. New Engl. J. Med. 371, 2092-2100, doi: 10.1056/NEJMoa1411680 (2014).
3. Boisen, M. L. et al. Multiple Circulating Infections Can Mimic the Early Stages of Viral Hemorrhagic Fevers and Possible Human Exposure to Filoviruses in Sierra Leone Prior to the 2014 Outbreak. Viral Immunol. 28, 19-31, doi: 10.1089/vim.2014.0108 (2014).
4. Schoepp, R. J., Rossi, C. A., Khan, S. H., Goba, A., Fair, J. N. Undiagnosed Acute Viral Febrile Illnesses, Sierra Leone. Emerging Infect. Dis. 20, 1176, doi: 10.3201/eid2007.131265 (2014).
5. Rowe, A. K. et al. Clinical, Virologic, and Immunologic Follow-Up of Convalescent Ebola Hemorrhagic Fever Patients and Their Household Contacts, Kikwit, Democratic Republic of the Congo. J. Infect. Dis. 179, S28-S35, doi: 10.1086/514318 (1999).
6. Mate, S. E. et al. Molecular Evidence of Sexual Transmission of Ebola Virus. New Engl. J. Med. 0, null, doi: doi: 10.1056/NEJMoa1509773 (2015).
7. Rodriguez, L. L. et al. Persistence and Genetic Stability of Ebola Virus during the Outbreak in Kikwit, Democratic Republic of the Congo, 1995. J. Infect. Dis. 179, S170-S176, doi: 10.1086/514291 (1999).
8. Bausch, D. G. et al. Assessment of the Risk of Ebola Virus Transmission from Bodily Fluids and Fomites. J. Infect. Dis. 196, S142-S147, doi: 10.1086/520545 (2007).
9. Varkey, J. B. et al. Persistence of Ebola Virus in Ocular Fluid during Convalescence. New Engl. J. Med. 372, 2423-2427, doi: 10.1056/NEJMoa1500306 (2015).
10. Akerlund, E., Prescott, J., Tampellini, L. Shedding of Ebola Virus in an Asymptomatic Pregnant Woman. New Engl. J. Med. 372, 2467-2469, doi: 10.1056/NEJMc1503275 (2015).
11. Trombley, A. R. et al. Comprehensive Panel of Real-Time TaqMan™ Polymerase Chain Reaction Assays for Detection and Absolute Quantification of Filoviruses, Arenaviruses, and New World Hantaviruses. Am. J. Trop. Med. Hyg. 82, 954-960, doi: 10.4269/ajtmh.2010.09-0636 (2010).
12. Chertow, D. S. et al. Ebola Virus Disease in West Africa-Clinical Manifestations and Management. New Engl. J. Med. 371, 2054-2057, doi: 10.1056/NEJMp1413084 (2014).
13. Martin, P., Laupland, K. B., Frost, E. H., Valiquette, L. Laboratory diagnosis of Ebola virus disease. Intensive Care Med. 41, 895-898, doi: 10.1007/s00134-015-3671-y (2015).
14. Velasquez, G. E. et al. Time from infection to disease and infectiousness for Ebola virus disease, a systematic review. Clin. Infect. Dis., doi: 10.1093/cid/civ531 (2015).
15. Piercy, T. J., Smither, S. J., Steward, J. A., Eastaugh, L., Lever, M. S. The survival of filoviruses in liquids, on solid substrates and in a dynamic aerosol. J. Appl. Microbiol. 109, 1531-1539, doi: 10.1111/j.1365-2672.2010.04778.x (2010).
16. Jaax, N. et al. Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory. The Lancet 346, 1669-1671, doi: 10.1016/S0140-6736(95)92841-3 (1995).
17. Adalja, A. A. Sanctuary Sites: What Lies Behind Ebola Eye Infections, Sexual Transmission, and Relapses. Health Secur., doi: 10.1089/hs.2015.28999.aaa (2015).
18. Huang, Y. et al. Temporal Dynamics of Host Molecular Responses Differentiate Symptomatic and Asymptomatic Influenza A Infection. PLos Genet. 7, e1002234, doi: 10.1371/journal.pgen.1002234 (2011).
19. Woods, C. W. et al. A Host Transcriptional Signature for Presymptomatic Detection of Infection in Humans Exposed to Influenza H1N1 or H3N2. PLos One 8, e52198, doi: 10.1371/journal.pone.0052198 (2013).
20. Feldmann, H., Geisbert, T. W. Ebola haemorrhagic fever. The Lancet 377, 849-862, doi: 10.1016/S0140-6736(10)60667-8 (2011).
21. Wu, L., Fan, J., Belasco, J. G. MicroRNAs direct rapid deadenylation of mRNA. Proc. Natl. Acad. Sci. USA 103, 4034-4039, doi: 10.1073/pnas.0510928103 (2006).
22. Pritchard, C. C., Cheng, H. H., Tewari, M. MicroRNA profiling: approaches and considerations. Nat. Rev. Genet. 13, 358-369, doi: 10.1038/nrg3198 (2012).
23. Chen, X., Liang, H., Zhang, J., Zen, K., Zhang, C.-Y. Secreted microRNAs: a new form of intercellular communication. Trends Cell Biol. 22, 125-132, doi: 10.1016/j.tcb.2011.12.001 (2012).
24. Weber, J. A. et al. The microRNA spectrum in 12 body fluids. Clin. Chem. 56, 1733-1741 (2010).
25. Schwarzenbach, H., Nishida, N., Calin, G. A., Pantel, K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat. Rev. Clin. Oncol. 11, 145-156, doi: 10.1038/nrclinonc.2014.5 (2014).
26. Staedel, C., Darfeuille, F. MicroRNAs and bacterial infection. Cell. Microbiol. 15, 1496-1507, doi: 10.1111/cmi.12159 (2013).
27. Cullen, B. R. MicroRNAs as mediators of viral evasion of the immune system. Nat. Immunol. 14, 205-210, doi: 10.1038/ni.2537 (2013).
28. Sheng, M. et al. Hsa-miR-1246, hsa-miR-320a and hsa-miR-196b-5p inhibitors can reduce the cytotoxicity of Ebola virus glycoprotein in vitro. Sci. China Life Sci. 57, 959-972, doi: 10.1007/s11427-014-4742-y (2014).
29. Martins, K. et al. Characterization of clinical and immunological parameters during Ebola virus infection of rhesus macaques. Viral Immunol. 28, 32-41, doi: 10.1089/vim.2014.0085 (2015).
30. Geisbert, T. W. et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. The Lancet 362, 1953-1958, doi: 10.1016/S0140-6736(03)15012-X (2003).
31. Reed, D. S., Lackemeyer, M. G., Garza, N. L., Sullivan, L. J., Nichols, D. K. Aerosol exposure to Zaire ebolavirus in three nonhuman primate species: differences in disease course and clinical pathology. Microb. Infect. 13, 930-936, doi: 10.1016/j.micinf.2011.05.002 (2011).
32. Twenhafel, N. A. et al. Pathology of Experimental Aerosol Zaire Ebolavirus Infection in Rhesus Macaques. Vet. Pathol. 50, 514-529, doi: 10.1177/0300985812469636 (2013).
33. Conesa, A., Nueda, M. J., Ferrer, A., Talon, M. maSigPro: a method to identify significantly differential expression profiles in timecourse microarray experiments. Bioinformatics 22, 1096-1102, doi: 10.1093/bioinformatics/btl056 (2006).
34. Kotsiantis, S. B., Zaharakis, I., Pintelas, P. Supervised machine learning: A review of classification techniques. Informatica 31, 249-268 (2007).
35. Vapnik, V. N. Statistical Learning Theory. (John Wiley & Sons, Inc., 1998).
36. Fernandez-Delgado, M., Cernadas, E., Barro, S., Amorim, D. Do we need hundreds of classifiers to solve real world classification problems? J. Mach. Learn. Res. 15, 3133-3181 (2014).
37. Statnikov, A., Aliferis, C. F., Tsamardinos, I., Hardin, D., Levy, S. A comprehensive evaluation of multicategory classification methods for microarray gene expression cancer diagnosis. Bioinformatics 21, 631-643, doi: 10.1093/bioinformatics/bti033 (2005).
38. Statnikov, A., Wang, L., Aliferis, C. F. A comprehensive comparison of random forests and support vector machines for microarraybased cancer classification. BMC Bioinformatics 9, 319-319, doi: 10.1186/1471-2105-9-319 (2008).
39. Furey, T. S. et al. Support vector machine classification and validation of cancer tissue samples using microarray expression data. Bioinformatics 16, 906-914, doi: 10.1093/bioinformatics/16.10.906 (2000).
40. Guyon, I., Weston, J., Barnhill, S., Vapnik, V. Gene selection for cancer classification using support vector machines. Mach. Learn. 46, 389-422 (2002).
41. Vlachos, I. S. et al. DIANA-miRPath v3.0: deciphering microRNA function with experimental support. Nucleic Acids Res. 43, W460-466, doi: 10.1093/nar/gkv403 (2015).
42. Spengler, J. R. et al. Relationship Between Ebola Virus Real-Time Quantitative Polymerase Chain Reaction-Based Threshold Cycle Value and Virus Isolation From Human Plasma. J. Infect. Dis. 212, S346-S349, doi: 10.1093/infdis/jiv187 (2015).
43. Leroy, E. M. et al. Human asymptomatic Ebola infection and strong inflammatory response. The Lancet 355, 2210-2215, doi: 10.1016/S0140-6736(00)02405-3 (2000).
44. Kruger, J., Rehmsmeier, M. RNAhybrid: microRNA target prediction easy, fast and flexible. Nucleic Acids Res. 34, W451-454, doi: 10.1093/nar/gkl243 (2006).
45. Lecellier, C.-H. et al. A Cellular MicroRNA Mediates Antiviral Defense in Human Cells. Science 308, 557-560, doi: 10.1126/science.1108784 (2005).
46. Ahluwalia, J. K. et al. Human cellular microRNA hsa-miR-29a interferes with viral nef protein expression and HIV-1 replication. Retrovirology 5, 117, doi: 10.1186/1742-4690-5-117 (2008).
47. Huang, J. et al. Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat. Med. 13, 1241-1247, doi: 10.1038/nm1639 (2007).
48. Otsuka, M. et al. Hypersusceptibility to Vesicular Stomatitis Virus Infection in Dicer1-Deficient Mice is Due to Impaired miR24 and miR93 Expression. Immunity 27, 123-134, doi: 10.1016/j.immuni.2007.05.014 (2007).
49. Jopling, C. L., Yi, M., Lancaster, A. M., Lemon, S. M., Sarnow, P. Modulation of Hepatitis C Virus RNA Abundance by a Liver-Specific MicroRNA. Science 309, 1577-1581, doi: 10.1126/science.1113329 (2005).
50. Garamszegi, S. et al. Transcriptional correlates of disease outcome in anticoagulant-treated non-human primates infected with ebolavirus. PLos Negl. Trop. Dis. 8, e3061, doi: 10.1371/journal.pntd.0003061 (2014).
51. Wang, X. et al. Cardiomyocytes mediate anti-angiogenesis in type 2 diabetic rats through the exosomal transfer of miR-320 into endothelial cells. J. Mol. Cell. Cardiol. 74, 139-150, doi: 10.1016/j.yjmcc.2014.05.001 (2014).
52. Lee, J. E., Saphire, E. O. Ebolavirus glycoprotein structure and mechanism of entry. Future Virol. 4, 621-635, doi: 10.2217/fvl.09.56 (2009).
53. Saeed, M. F., Kolokoltsov, A. A., Freiberg, A. N., Holbrook, M. R., Davey, R. A. Phosphoinositide-3 kinase-Akt pathway controls cellular entry of Ebola virus. PLos Pathog. 4, e1000141, doi: 10.1371/journal.ppat.1000141 (2008).
54. Wahl-Jensen, V. M. et al. Effects of Ebola Virus Glycoproteins on Endothelial Cell Activation and Barrier Function. J. Virol. 79, 10442-10450, doi: 10.1128/jvi.79.16.10442-10450.2005 (2005).
55. Yang, Z.-y. et al. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat. Med. 6, 886-889, doi: 10.1038/78654 (2000).
56. Feldmann, H. et al. Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages. J. Virol. 70, 2208-2214 (1996).
57. Sonnenberg, P., Field, N. Sexual and Mother-to-Child Transmission of Ebola Virus in the Postconvalescent Period. Clin. Infect. Dis. 60, 974-975, doi: 10.1093/cid/ciu981 (2015).
58. Centers for Disease Control. Interim U.S. Guidance for Monitoring and Movement of Persons with Potential Ebola Virus Exposure. (Centers for Disease Control, Atlanta, GA, USA, 2014).
59. Cardile, A. P. et al. Monitoring Exposure to Ebola and Health of U.S. Military Personnel Deployed in Support of Ebola Control Efforts-Liberia, October 25, 2014-February 27, 2015. MMWR Morb. Mortal. Wkly. Rep. 64, 690-694 (2015).
60. Bellan, S. E., Pulliam, J. R. C., Dushoff, J., Meyers, L. A. Ebola control: effect of asymptomatic infection and acquired immunity. The Lancet 384, 1499-1500, doi: 10.1016/S0140-6736(14)61839-0 (2014).
61. Geisbert, T. W., Strong, J. E., Feldmann, H. Considerations in the Use of Nonhuman Primate Models of Ebola Virus and Marburg Virus Infection. J. Infect. Dis. 212, S91-S97, doi: 10.1093/infdis/jiv284 (2015).
62. Rubins, K. H. et al. The temporal program of peripheral blood gene expression in the response of nonhuman primates to Ebola hemorrhagic fever. Genome Biol. 8, R174 doi: 10.1186/gb-2007-8-8-r174 (2007).
63. National Research Council. Guide for the Care and Use of Laboratory Animals. 8th edn, (The National Academies Press, 2011).
64. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report: Ethical principles and guidelines for the protection of human subjects of research (1979).
65. Smith, D. W., Rawlinson, W. D., Kok, J., Dwyer, D. E., Catton, M. Virological diagnosis of Ebolavirus infection. Pathology 47, 410-413 doi: 10.1097/pat.0000000000000292 (2015).
66. Duy, J., Koehler, J. W., Honko, A. N., Minogue, T. D. Optimized microRNA purification from TRIzol-treated plasma. BMC Genomics 16, 1-9 (2015).
67. Sozhamannan, S. et al. Evaluation of Signature Erosion in Ebola Virus Due to Genomic Drift and Its Impact on the Performance of Diagnostic Assays. Viruses 7, 3130-3154 doi: 10.3390/v7062763 (2015).
68. Mestdagh, P. et al. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol. 10, R64 doi: 10.1186/gb-2009-10-6-r64 (2009).
69. R. Core Team R: A language and environment for statistical computing. R Foundation for Statistical Computing,Vienna, Austria. URL: http://www.R-project.org/(2014).